Literature DB >> 32603552

Global microRNA profiling identified miR-10b-5p as a regulator of neurofibromatosis 1 (NF1)-glioma migration.

J S Nix1, M Yuan1, E L Imada2, H Ames3, L Marchionni2, D H Gutmann4, F J Rodriguez1,5,2.   

Abstract

AIMS: Neurofibromatosis 1 (NF1) is an autosomal-dominant cancer predisposition syndrome caused by loss of function alterations involving the NF1 locus on chromosome 17. The most common brain tumours encountered in affected patients are low-grade gliomas (pilocytic astrocytomas), although high-grade gliomas are also observed at increased frequency. While bi-allelic NF1 loss characterizes these tumours, previous studies have suggested noncoding RNA molecules (microRNA, miR) may have important roles in dictating glioma biology.
METHODS: To explore the contributions of miRs in NF1-associated gliomas, we analysed five high-grade gliomas (NF1-HGG) and five PAs (NF1-PA) using global microRNA profiling with NanoString-based microarrays followed by functional experiments with glioma cell lines.
RESULTS: miR-10b-5p, miR-135b-5p, miR-196a-5p, miR-196b-5p, miR-1247-5p and miR-320a (adjusted P < 0.05) were increased> 3-fold in NF1-HGG relative to NF1-PA tumours. In addition, miR-378b and miR-1305 were decreased 6.8- and 6-fold, respectively, whereas miR-451a was increased 2.7-fold (adjusted P < 0.05) in NF1-PAs compared to non-neoplastic NF1 patient brain specimens (n = 2). As miR-10b-5p was the microRNA overexpressed the most in NF1-high-grade glioma compared to NF1-low-grade glioma (5.76 fold), we examined its levels in glioma cell lines. miR-10b-5p levels were highest in adult glioma cell lines and lowest in paediatric low-grade glioma lines (P = 0.02). miR-10b-5p knockdown resulted in decreased invasion in NF1-deficient LN229 high-grade glioma line, whereas its overexpression in the NF1-PA derived line (JHH-NF1-PA1) led to increased invasion. There was no change in cell growth (viability and proliferation).
CONCLUSIONS: These proof-of-concept experiments support a role for microRNA regulation in NF1-glioma biology.
© 2020 British Neuropathological Society.

Entities:  

Keywords:  NF1; glioma; miR-10b; microRNA; neurofibromatosis

Year:  2020        PMID: 32603552     DOI: 10.1111/nan.12641

Source DB:  PubMed          Journal:  Neuropathol Appl Neurobiol        ISSN: 0305-1846            Impact factor:   8.090


  5 in total

1.  ALKBH5 promotes the progression of infantile hemangioma through regulating the NEAT1/miR-378b/FOSL1 axis.

Authors:  Kun Peng; Ren-Peng Xia; Fan Zhao; Yong Xiao; Ti-Dong Ma; Ming Li; Yong Feng; Chong-Gao Zhou
Journal:  Mol Cell Biochem       Date:  2022-02-18       Impact factor: 3.396

2.  Therapeutic Vulnerability to ATR Inhibition in Concurrent NF1 and ATRX-Deficient/ALT-Positive High-Grade Solid Tumors.

Authors:  Ming Yuan; Charles G Eberhart; Christine A Pratilas; Jaishri O Blakeley; Christine Davis; Marija Stojanova; Karlyne Reilly; Alan K Meeker; Christopher M Heaphy; Fausto J Rodriguez
Journal:  Cancers (Basel)       Date:  2022-06-19       Impact factor: 6.575

3.  MiR-1248: a new prognostic biomarker able to identify supratentorial hemispheric pediatric low-grade gliomas patients associated with progression.

Authors:  Giuseppina Catanzaro; Zein Mersini Besharat; Andrea Carai; Natalie Jäger; Elena Splendiani; Carole Colin; Agnese Po; Martina Chiacchiarini; Anna Citarella; Francesca Gianno; Antonella Cacchione; Evelina Miele; Francesca Diomedi Camassei; Marco Gessi; Luca Massimi; Franco Locatelli; David T W Jones; Dominique Figarella-Branger; Stefan M Pfister; Angela Mastronuzzi; Felice Giangaspero; Elisabetta Ferretti
Journal:  Biomark Res       Date:  2022-06-17

4.  Hypoxic glioma-derived extracellular vesicles harboring MicroRNA-10b-5p enhance M2 polarization of macrophages to promote the development of glioma.

Authors:  Bingzhen Li; Cheng Yang; Zhanpeng Zhu; Hao Chen; Bin Qi
Journal:  CNS Neurosci Ther       Date:  2022-09-02       Impact factor: 7.035

Review 5.  Reimagining pilocytic astrocytomas in the context of pediatric low-grade gliomas.

Authors:  Till Milde; Fausto J Rodriguez; Jill S Barnholtz-Sloan; Nirav Patil; Charles G Eberhart; David H Gutmann
Journal:  Neuro Oncol       Date:  2021-10-01       Impact factor: 13.029

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.